Description

Anticoagulants are medicines that help prevent blood clots. They’re given to people at a high risk of getting clots, to reduce their chances of developing serious conditions such as strokes and heart attacks. The global anticoagulation market is poised to grow by US$ 9.6 billion during 2022-2028, progressing at a CAGR of 6.8% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for anticoagulation. The global anticoagulation market is segmented on the basis of product, disease indication, route of administration, distribution channel, and region. By product, the global anticoagulation market has been segmented into direct oral anticoagulants (DOACs), low-molecular-weight heparins (LMWHs), vitamin k antagonists (VKAs), warfarin. According to the research, the DOACs segment had the largest share in the global anticoagulation market. Based upon disease indication, the global anticoagulation market is categorized into deep vein thrombosis (DVT) & pulmonary embolism (PE), heart attack, mechanical heart valves (MHV), stroke, others. On the basis of route of administration, the global anticoagulation market has been segmented into injectable, oral, others. Among these, the oral segment was accounted for the highest revenue generator in 2021. By distribution channel, the global anticoagulation market has been segmented into hospitals, online pharmacies, pharmacies. Geographically, the global anticoagulation market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

Key companies profiled in the report include Daiichi Sankyo Company Limited, GSK plc (formerly GlaxoSmithKline plc), Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the anticoagulation market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: direct oral anticoagulants (DOACs), low-molecular-weight heparins (LMWHs), vitamin k antagonists (VKAs), warfarin
Disease indication: deep vein thrombosis (DVT) & pulmonary embolism (PE), heart attack, mechanical heart valves (MHV), stroke, others
Route of administration: injectable, oral, others
Distribution channel: hospitals, online pharmacies, pharmacies
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global anticoagulation market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Anticoagulation market overview
Part 3. Market breakdown by product
– Direct oral anticoagulants (DOACs)
– Low-molecular-weight heparins (LMWHs)
– Vitamin k antagonists (VKAs)
– Warfarin
Part 4. Market breakdown by disease indication
– Deep vein thrombosis (DVT) & pulmonary embolism (PE)
– Heart attack
– Mechanical heart valves (MHV)
– Stroke
– Others
Part 5. Market breakdown by route of administration
– Injectable
– Oral
– Others
Part 6. Market breakdown by distribution channel
– Hospitals
– Online pharmacies
– Pharmacies
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 8. Key companies
– Daiichi Sankyo Company, Limited
– GSK plc (formerly GlaxoSmithKline plc)
– Johnson & Johnson
– Novartis AG
– Pfizer Inc.
– Sanofi S.A.
About StrategyHelix
Disclaimer